Epidermolysis Bullosa Market Size, Trends, Industry Analysis, Overview, Share And Forecast 2023 To 2030

-


Market Overview:

Epidermolysis bullosa (EB) is a group of rare genetic conditions that cause easy blistering of the skin and mucous membranes. The condition ranges from very mild to severe. In severe forms, even minor friction or trauma causes large blisters or skin loss. The major treatment modalities available include wound care, pain management, surgery, and autologous cell therapy. 

The global Epidermolysis Bullosa Market is estimated to be valued at US$ 3,429.30 Mn in 2023 and is expected to exhibit a CAGR of 11. % over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights. 

Market key trends:

One of the major trends in the EB market is increasing R&D for autologous cell therapy. Autologous cell therapy involves transplantation of the patient's own genetically corrected cells to restore the function of defective genes. Researchers are evaluating autologous cell therapies such as gene-corrected fibroblast transplantation and induced pluripotent stem cell transplantation to provide permanent cure for EB. Companies such as Amryt Pharma and Abeona Therapeutics are developing gene therapy and autologous stem cell transplantation treatments offering encouraging results in clinical trials. Other ongoing research includes development of biological skin equivalents and topical products to treat wounds and protect skin barrier function in EB patients.

Get more insights on this topic: https://www.coherentmarketinsights.com/market-insight/epidermolysis-bullosa-therapeutics-market-2214

Segment Analysis 

The global epidermolysis bullosa market is segregated into junctional EB, dominant dystrophic EB, and recessive dystrophic EB, based on disease type. The dominant dystrophic EB segment dominated the market in 2022 and is estimated to witness high growth over the forecast period. Dominant dystrophic EB is the most common form of EB and is characterized by mechanically fragile skin and mucous membranes. Easy blistering and shearing of the skin layers are common symptoms of dominant dystrophic EB. 

Key Takeaways

The global epidermolysis bullosa market size was valued at US$ 3,429.30 Mn in 2023 and is expected to reach US$ 7,385.97 Mn by 2030, growing at a CAGR of 11% over the forecast period.

Regional Analysis

North America dominated the global market in 2022 and is estimated to maintain its dominance over the forecast period, growing at a CAGR of 11.3%. This is attributed to the increasing prevalence of EB, rising research funding for developing therapies, and presence of key pharmaceutical companies in the region. 

Key Players Analysis 

Key players operating in the epidermolysis bullosa market are Amryt Pharma, Abeona Therapeutics, Castle Creek Pharmaceuticals, RegeneRx, Krystal Biotech, RHEACELL GmbH, Holostem Terapie Avanzate, StemRim/Shionogi, and Phoenix Tissue Repair. Amryt Pharma's Oleogel-S10 is the only FDA approved topical treatment for EB. Krystal Biotech is developing an innovative gene therapy for dystrophic EB.

Comments

Post a Comment

Popular posts from this blog

Radiopharmaceuticals in Nuclear Medicine Market to Surpass US$ 11,504.8 Million by 2027

-
Image
There are numerous radiopharmaceuticals available for both therapeutic and diagnostic purposes, each with distinct and overlapping indications for specific disorders like Alzheimer's (Vizamyl, Amyvid, and Neuraceq). There are around 50 radiopharmaceuticals with U.S. FDA approval available for both therapeutic and diagnostic uses, with Technetium alone having over 30 approved compounds. Business Dynamics In order to increase their market presence, industry players are focusing on a variety of inorganic growth tactics including partnership and cooperation agreements, which is anticipated to accelerate the growth of the worldwide radiopharmaceuticals in nuclear medicine market over the forecast period. For instance, a distribution contract was signed by Cardinal Health Inc. and Telix Pharmaceuticals Inc., a division of Telix Pharmaceuticals Limited, in October 2018. In accordance with the contract, Cardinal Health will provide the 69Ga-PSMA Kit as well as create unit dosages of 68Ga-...
Read more

The Where and the How: Unraveling Biology's Spatial Enigma with Omics

-
Image
In the fast-evolving landscape of biomedical research, a revolutionary technique has emerged that promises to unlock new dimensions of understanding within cellular landscapes – Spatial Omics. This cutting-edge approach combines the power of genomics, transcriptomics, proteomics, and more, with spatial information, creating a holistic view of biological systems. At its core, Spatial Omics involves mapping the molecular composition of tissues with spatial context. Traditional omics techniques provide valuable insights into the molecules present in a sample, but they lack the crucial information about where these molecules are located within the tissue. Spatial Omics bridges this gap by preserving the spatial architecture, offering unprecedented insights into cellular interactions, organization, and function. Read More @   https://www.digitaljournal.com/pr/news/coherent-market-insights/spatial-omics-market-revenue-growth-rate-customer-needs-trend-manufacturers-and-forecast-to-2030-10...
Read more

Nanorobotics: Unlocking New Possibilities in Targeted Drug Delivery

-
Image
The nanorobotics industry involves engineering devices at the scale of nanometers to micrometers in order to perform tasks such as assembly and manipulation at molecular levels. Nanorobotic technologies have potential applications across various domains including biomedical sciences, agriculture, environmental remediation, material synthesis, and more. By enabling miniaturization, nanorobotic tools are able to precisely target and interact with cells and molecules within the human body, providing new methods for disease diagnosis and treatment.  The global nanorobotics market is estimated to be valued at USD 989.7 million in 2024 and is expected to exhibit a CAGR of 4.5% over the forecast period from 2023 to 2030. Key applications of nanorobots include targeted drug delivery, biological sensors, tissue engineering, molecular surgery, and biomedical research. For instance, nanorobots injected intravenously could be programmed to travel through blood vessels and locate microscopic tu...
Read more